The Effects of Pembrolyzum on the Progression Free Survival of DMMR and PMMR Patients

At 12 months 74% of patients who were treated with Pembrolyzum app were without evidence of disease progression or death compared to 38% of those who received placebo. In the PMMR or mismatch repair proficient population we saw consistent benefit, median progression free survival was 13.1 months versus 8.7 months in the placebo arm and a hazard ratio of 0.30 p-value less than 0.00001.